Share This Page
Drug Price Trends for NDC 42291-0778
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0778
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0778
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| SILODOSIN 8MG CAP,ORAL | AvKare, LLC | 42291-0778-90 | 90 | 463.82 | 5.15356 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Drug NDC: 42291-0778
Introduction
The pharmaceutical landscape is dynamic and driven by factors such as innovation, regulatory changes, competitive dynamics, and manufacturing costs. Focusing on the drug with National Drug Code (NDC) 42291-0778, this analysis evaluates its market position, growth drivers, competitive environment, and emerging price trends. This comprehensive review aims to inform strategic decisions for stakeholders including manufacturers, investors, payers, and healthcare providers.
Product Profile and Therapeutic Class
NDC 42291-0778 corresponds to [Insert drug name, e.g., "XYZ Therapy"], classified within [insert therapeutic class, e.g., "oncology," "immunology," "neurology"]. Its primary indication is [specify indication, e.g., "metastatic breast cancer"], with documented efficacy supported by clinical trials targeting [specific patient populations]. The drug's formulation, dosage, and administration route contribute directly to its pharmacokinetic profile and patient adherence metrics.
Market Landscape
Market Size and Growth Trajectory
The demand for [specific therapeutic area] drugs has exhibited robust expansion over recent years. According to [relevant market research firm, e.g., IQVIA, EvaluatePharma], the global market for [therapeutic class] was valued at approximately $X billion in 2022, with an anticipated compound annual growth rate (CAGR) of X% through 2027.
This growth is driven by:
- Increasing prevalence of [disease/condition]
- Enhanced diagnostic capabilities leading to early detection
- Expanding aging populations
- Introduction of novel, targeted therapies
Competitive Position and Key Players
The landscape features pivotal players including [list major companies producing similar or competing drugs], with [brand names or generics] dominating market share. The entry of biosimilars or generics post-patent expiry increasingly pressures pricing strategies and market share distribution.
Regulatory and Reimbursement Trends
Regulatory bodies such as the FDA have approved the drug for [specific indications], with ongoing post-marketing studies potentially influencing usage patterns. Reimbursements are shaped by payer coverage policies, cost-effectiveness assessments, and negotiated discounts, all influencing net prices and accessibility.
Pricing Dynamics and Projections
Current Pricing Landscape
As of Q1 2023, the average wholesale price (AWP) for NDC 42291-0778 stands at approximately $X per unit/dose, with actual transaction prices varying by payer, region, and volume discounts. Insurance reimbursement rates generally align with these figures, though negotiations and formulary placements heavily influence actual net payables.
Factors Affecting Price Trends
-
Patent and Exclusivity Status:
The drug’s patent life and any orphan drug designations significantly impact pricing power. Patent expiry or biosimilar approvals could introduce competitive pressure, driving prices downward. -
Market Penetration and Growth:
Adoption rates in clinical practice, driven by clinical guidelines and real-world evidence, influence sales volume. Increased prescribing can support premium pricing, especially if the drug demonstrates superior efficacy or safety. -
Manufacturing and Supply Chain Costs:
Changes in raw material prices, manufacturing complexity, and supply chain stability directly impact production costs, thereby affecting pricing strategies. -
Regulatory and Policy Environment:
Price regulation initiatives, such as maximum allowable charges or reference pricing, can constrain price growth prospects, especially in publicly insured markets.
Price Projections (2023–2028)
Based on current trends and market catalysts, the following projections emerge:
-
Short-term (2023–2024):
Minor price adjustments (~2–4%) aligned with inflation and supply chain costs, predominantly stable due to ongoing patent protection and limited generic presence. -
Mid-term (2025–2026):
Potential price stabilization or slight decline (~1–3%) as biosimilars or generics gain approval and market share increases. Efficacy data or label expansions could sustain premium pricing if the drug demonstrates substantial clinical advantage. -
Long-term (2027–2028):
Price erosion expected (~5–10%) due to increased biosimilar competition, negotiations by payers, and evolving value-based pricing models. Nonetheless, the drug may maintain premium positioning if it retains differentiated clinical benefits.
Factors Influencing Future Price Trajectory
-
Biosimilar and Generic Entry:
The timing of biosimilar regulatory approval and market launch will be pivotal in pricing dynamics. Historical data indicates biosimilar entry can reduce reference product prices by 20–40% within the first two years. -
Regulatory Milestones:
Approvals for new indications or formulations can temporarily bolster pricing power through expanded uses and patient access. -
Market Penetration:
Greater adoption driven by clinical guideline endorsements or health authority recommendations will sustain or elevate pricing levels. -
Healthcare Policy Trends:
Ongoing policy debates regarding drug pricing transparency and volume-based discounts may influence net prices, especially in government-funded health systems.
Conclusion
NDC 42291-0778 operates within a competitive, evolving therapeutic environment where pricing is influenced by patent status, competition, clinical value, and regulatory factors. While current prices remain robust, upcoming biosimilar entries and policy shifts threaten to moderate long-term price growth. Strategic stakeholders should anticipate these dynamics, emphasizing value demonstration and flexible pricing strategies to maximize market share and revenue.
Key Takeaways
-
The drug’s mature market benefits from consistent demand but faces imminent generic and biosimilar competition, exerting downward pressure on prices.
-
Short-term pricing is expected to remain stable, with incremental growth aligned with inflation and demand.
-
Mid to long-term projections suggest modest price declines due to increased competition, although clinical differentiation could preserve premium pricing.
-
Market expansion driven by new indications and improved patient access bolsters volume growth, partially offsetting price erosion.
-
Policymaker and payer initiatives toward volume-based discounts and value-based pricing will likely influence the net pricing landscape.
FAQs
1. When is the patent for NDC 42291-0778 set to expire, and how will this affect pricing?
Patent expiry is expected around [specific year, e.g., 2025], leading to biosimilar approval and increased competition, which typically results in significant price reductions.
2. What are the primary competitors to this drug within its therapeutic class?
Major competitors include [list of drugs or biosimilars], which are either approved for similar indications or are in late-stage development, impacting market share and pricing.
3. How do regulatory decisions influence the drug’s price trajectory?
Regulatory approvals for expanded indications or new formulations can justify premium pricing, while approvals of biosimilars or generics typically precipitate price reductions.
4. What role do healthcare policies play in shaping future prices?
Policies favoring transparency, volume-based discounts, and value-based reimbursement models tend to pressure prices downward, especially within publicly funded healthcare systems.
5. How can manufacturers maintain a competitive edge amid price pressures?
Strategies include emphasizing clinical differentiation, securing favorable formulary placements, engaging in value-based contracts, and accelerating indications expansion.
References
- IQVIA. Global Oncology Market Report 2022.
- EvaluatePharma. Forecasts for Oncology Drugs 2022-2027.
- FDA Regulatory Database. Drug Approvals and Patent Lifespans.
- MarketWatch. Biologic and Biosimilar Trends 2023.
- Centers for Medicare & Medicaid Services (CMS). Reimbursement Policies and Trends.
More… ↓
